BACKGROUND: Early diagnosis of recurrent breast cancer is crucial to selection of the most appropriate therapy. The current study evaluated the role of FDG-PET/CT in the assessment of suspected recurrent breast cancer in patients who presented with elevated serum tumor markers. METHODS: Forty-seven consecutive FDG-PET/CT studies of 46 women (aged 32-79 years; mean, 59.9 years) with a history of breast cancer presented with elevated serum tumor markers 1-21 years (mean = 6.2 years) after their initial diagnosis and were retrospectively evaluated. PET/CT results were confirmed by pathology (n = 11), further imaging, and follow-up (mean = 17.2 months; n = 36). Changes in further management based on PET/CT were recorded. RESULTS: Thirty (65%) patients had tumor recurrence, and 16 (35%) patients showed no further evidence of disease. Thirty-one patients had 32 abnormal PET/CT studies, and 15 patients had normal studies with an overall sensitivity, specificity, and accuracy of 90%, 71%, and 83%, respectively. In 37 patients, PET/CT was compared with contrast-enhanced CT and had a higher sensitivity (85% vs 70%), specificity (76% vs 47%), and accuracy (81% vs 59%). PET/CT had an impact on the management of 24 (5l%) patients. Of these, chemotherapy or radiotherapy was started in 16 patients, treatment was modified in 2 patients, and 6 patients were referred to biopsy, followed by referral to surgery for 2 patients. CONCLUSIONS: In patients with breast cancer and rising tumor markers, FDG-PET/CT had high performance indices and was superior to CT for diagnosis of tumor recurrence, which led to changes in the subsequent clinical management of 51% of these patients. (c) 2006 American Cancer Society.
BACKGROUND: Early diagnosis of recurrent breast cancer is crucial to selection of the most appropriate therapy. The current study evaluated the role of FDG-PET/CT in the assessment of suspected recurrent breast cancer in patients who presented with elevated serum tumor markers. METHODS: Forty-seven consecutive FDG-PET/CT studies of 46 women (aged 32-79 years; mean, 59.9 years) with a history of breast cancer presented with elevated serum tumor markers 1-21 years (mean = 6.2 years) after their initial diagnosis and were retrospectively evaluated. PET/CT results were confirmed by pathology (n = 11), further imaging, and follow-up (mean = 17.2 months; n = 36). Changes in further management based on PET/CT were recorded. RESULTS: Thirty (65%) patients had tumor recurrence, and 16 (35%) patients showed no further evidence of disease. Thirty-one patients had 32 abnormal PET/CT studies, and 15 patients had normal studies with an overall sensitivity, specificity, and accuracy of 90%, 71%, and 83%, respectively. In 37 patients, PET/CT was compared with contrast-enhanced CT and had a higher sensitivity (85% vs 70%), specificity (76% vs 47%), and accuracy (81% vs 59%). PET/CT had an impact on the management of 24 (5l%) patients. Of these, chemotherapy or radiotherapy was started in 16 patients, treatment was modified in 2 patients, and 6 patients were referred to biopsy, followed by referral to surgery for 2 patients. CONCLUSIONS: In patients with breast cancer and rising tumor markers, FDG-PET/CT had high performance indices and was superior to CT for diagnosis of tumor recurrence, which led to changes in the subsequent clinical management of 51% of these patients. (c) 2006 American Cancer Society.
Authors: C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner Journal: Eur J Nucl Med Mol Imaging Date: 2012-03-06 Impact factor: 9.236
Authors: Till-Alexander Heusner; Sherko Kuemmel; Angela Koeninger; Monia E Hamami; Steffen Hahn; Anton Quinsten; Andreas Bockisch; Michael Forsting; Thomas Lauenstein; Gerald Antoch; Alexander Stahl Journal: Eur J Nucl Med Mol Imaging Date: 2010-03-04 Impact factor: 9.236
Authors: Spencer L Bowen; Yibao Wu; Abhijit J Chaudhari; Lin Fu; Nathan J Packard; George W Burkett; Kai Yang; Karen K Lindfors; David K Shelton; Rosalie Hagge; Alexander D Borowsky; Steve R Martinez; Jinyi Qi; John M Boone; Simon R Cherry; Ramsey D Badawi Journal: J Nucl Med Date: 2009-08-18 Impact factor: 10.057
Authors: Seok-Ho Yoon; Ku Sang Kim; Seok Yun Kang; Hee-Sung Song; Kyung Sook Jo; Bong-Hoi Choi; Su Jin Lee; Joon-Kee Yoon; Young-Sil An Journal: Nucl Med Mol Imaging Date: 2012-10-27